1INTRODUCTIONNeuroendocrine neoplasms (NENs) are epithelial tumors with a predominant neuroendocrine differentiation, which originate in a great diversity of tissues. The results from the National Cancer Registry for Gastroenteropancreatic Neuroendocrine Tumors (RGETNE) have shown that approximately half of all NENs are GI‐NENs, with highest frequency being observed in the small intestine, appendix and stomach, which significantly differ with that observed in Surveillance, Epidemiology and End Results (SEER) Program tumor registry. The incidence of NENs varies between 3.24 and 6.50/100 000, a trend for higher incidence in men compared with women. In addition, GI‐NENs accounted for an increasing proportion of NENs. According to the SEER database, the incidence rate of GI‐NENs was 5.25/100 000 in 2004, with a five‐fold increase from that 30 years earlier. This increase was likely caused in part by improvements in classification of these tumors. Nowadays, surgical resection undoubtedly remains the mainstay of the potentially curative treatment for the GI‐NENs. However, NENs may be asymptomatic and clinically silent when diagnosed but some will display malignant characteristics even underwent surgical resection; they often have unpredictable biological behavior.Currently, there is no accepted uniformed grading system for NENs. The ability to stratify patients with NENs into prognostic groups could yield benefits to
Asia-Pacific Journal of Clinical Oncology – Wiley
Published: Jan 1, 2018
Keywords: ; ;
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera